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SUMMARY We report the case of a 45-year old man with non-
healing ulcers located on his chest, lumbal, sacral, retroauricular 
areas and forehead. Both clinical and histopathological examina-
tions suggested pyoderma gangrenosum (PG). For six months 
the diagnosis of ulcerative colitis was established. PG in our 
patient was presented as a rapidly enlarging, painful ulcer with 
purple, undermined edges and a necrotic, haemorrhagic base. 
Initially, he was treated with a high dosage of peroral glucocor-
ticosteroid, sulfasalazine, and systemic antibiotics, together with 
daily wound care. Ulceration partially regressed. Total colonos-
copy showed pancolitis. When the dose of glucocorticosteroids 
was tapered down to 35 mg, new ulcerations on his right thigh 
and abdomen were formed. He also developed E. coli sepsis and 
flare up of bowel disease. Azathioprine, together with two pulse 
doses of glucocorticosteroids and antibiotics, were administered. 
He was scheduled for a total colectomy.
The management of PG continues to be a therapeutic challenge.




 Pyoderma gangrenosum (PG) is an idiopathic 
inflammatory disease of unknown etiology, fre-
quently associated with an underlying systemic 
condition such as inflammatory bowel disease, im-
munologic disease or haematological malignancy 
(1,2). Its occurrence tends to parallel exacerba-
tions of the underlying disease.
CASE REPORT
 A 45-year-old male patient was suffering 
from ulcerative colitis when he suddenly devel-
oped small erythematous papules then pustules 
together with fever and diarrhea. The diagnosis 
of ulcerative colitis was established for 6 months 
according to clinical, laboratory, radiological and 
endoscopic criteria. At that time, he was taking 
peroral glucocorticosteroid (60 mg prednisone) 
and sulfasalazine.
 Skin ulcerations became larger, located on his 
chest, lumbal, sacral, left retroauricular region and 
on his forehead (Figs. 1 and 2). Ulcer borders 
were irregular, raised, boggy, undermined and 
very painful. 
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A biopsy specimen from the wound margin showed 
dense nodular infiltrate of neutrophils extending 
through the deep dermis (Fig. 3). There was peri-
follicular inflammation, leukocytoclastic vasculi-
tis with fibrin in the wall of venules together with 
peri- and intra-vascular infiltration of neutrophils 
with nuclear dust. Tissue bacterial swabs showed 
Staphyloccocus epidermidis in one ulceration, 
while others were sterile. Tissue swabs excluded 
fungal and mycobacterial infections. 
 Ulcerative colitis also flared up. A total colo-
noscopy showed pancolitis with ulcerations and 
inflammatory pseudopolyps indicating severely 
active and long-lasting disease.
 The patient was initially treated with a high 
dose of peroral glucocorticosteroid (80 mg predni-
sone) orally, sulfasalazine, and systemic antibiotic 
together with daily wound care. Ulcers were gently 
cleaned by applying wet compresses containing 
normal saline and covered with moisture-retentive 
dressings to prolong drug activity and hasten the 
healing process. On the few smaller ulcers, locat-
ed retroauriculary occlusive hydrocolloidal dress-
ings were applied. Ulcerations became smaller 
and shallower; gastrointestinal (GI) symptoms 
were reduced. 
 The glucocorticosteroid dose was gradually ta-
pered down, and at 35 mg, GI symptoms worsened 
again, presented with diarrhea and fever again. E. 
coli sepsis was diagnosed. Laboratory findings 
showed a high sedimentation rate, leucocytosis, a 
high level of C reactive protein concentrations and 
elevated liver function tests.
 Within the following two days, new ulcerations 
appeared on the abdomen and right thigh. They 
were up to 15 cm in diameter, with purulent, par-
tially (at the edge) covered by necrotic eschar and 
Figure 1. Multiple PG ulcerations with irregular, 
raised borders covered with yellow granulomatose 
tissue
Figure 2. PG ulceration on the left retroauricular 
region
Figure 3. A biopsy specimen from the wound mar-
gin showed dense nodular infiltrate of neutrophils 
extending through the deep dermis. There is peri-
follicular inflammation, leukocytoclastic vasculitis 
with fibrin in the wall of venules. Haemotoxyllin-
eosin stain;x25
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mild hemorrhagic exudates (Figs. 4 and 5). Sig-
moidoscopy showed multiple pseudopolyps and 
inflammation changes of bowel mucosa (Fig. 6). 
A biopsy of the polyp showed low-grade dyspla-
sia, and he was scheduled for a colectomy. He re-
ceived two pulse doses of methylprednisone i.v., 
with 100 mg azathioprine. Because of the sepsis, 
antibiotics were administered as well. A few weeks 
later, both the skin and GI symptoms improved 
(Fig. 7). He is now awaiting an operation.
DISCUSSION
 Pyoderma gangrenosum was first described in 
1930 by Brunsting and coworkers (3). It was origi-
nally thought to be a bacterial disease.
 The etiology of PG remains unknown. Fifty 
percent of the cases of PG are associated with 
chronic disease, including ulcerative colitis and 
Crohn’s disease, chronic active hepatitis, rheu-
matoid arthritis, seronegative arthritis, monoclo-
nal gammopathy, diabetes or malignancies. The 
other 50% of cases have no associated disease 
and are considered idiopathic (4,5). All ages may 
be affected, but PG predominantly occurs in the 
fourth and fifth decades of life. It affects both 
sexes, but there is a slight predominance in fe-
males. Children and adolescents may be affected 
as well (6). There are four main clinical variants of 
PG (ulcerative, pustular, bullous, and vegetative), 
but the ulcerative form is by far the most prevalent 
(6). An ulcer usually tends to occur on the lower 
extremities, trunk, and occasionally on the head 
and neck, and even on genitalia (6-8). Our patient 
developed ulcers on the abdominal wall and the 
Figure 4 and Figure 5. PG ulceration with purulent content, partially covered by necotic eschar, with mild 
hemorrhagic exudates
Figure 6. Colonoscopy. Ulceration and multiple 
inflammatory polyps of sygmoid colon Figure 7. Cicatrix on the left retroauricular region
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retroauricular and sternal regions. He later had an 
exacerbation, and he developed a large ulcer on 
his right upper leg.
 Patients usually describe the initial lesion as a 
bite-like reaction, with a small, red papule or pus-
tule changing into a larger ulcerative lesion with an 
undermined and violaceous edge. These ulcers 
may grow to be as large as 20 cm and may have 
satellite lesions and multiple ulcers associated with 
it. In our patient, primary lesions were pustules 
that rapidly became larger-forming big ulcers. Le-
sions often result from minor local trauma, which 
is a process known as pathergy (4). Pathergy is a 
term that describes ulcer formation that occurs at 
sites of minimal trauma. Ulcers are very painful, 
the borders are irregular, undermined, and usually 
heal with a cribriform scar (5).
 No specific pathologic or laboratory finding 
exists, and the condition may be persistent even 
with a negative biopsy. The histopathology of PG 
is non-specific but is useful to exclude other ulcer-
ative and neoplastic disease. Necrosis is charac-
teristically present with neutrophils and fibrin in the 
superficial vessels, or thrombosis of small vessels. 
Often it is part of a mixed cellular neutrophilic infil-
trate accompanied by lymphocytes, plasma cells, 
histiocytes and even giant cells, all of which may 
be distributed around follicles. 
 For PG diagnosis and treatment, a multidisci-
plinary approach including a dermatologist, gas-
troenterologist, pathologist, rheumatologist and 
podiatrist is often necessary. The treatment of PG 
is based on the nature and extent of the lesion, 
and includes therapy for underlying associated 
disease.
 Local therapy is directed toward the relief of 
pain and the prevention of a secondary wound 
infection. Dressings may consist of topical steroids 
or a hydrogel to promote moist wound healing. 
Wet-to-dry dressings, rest, limb elevation, potent 
topical corticosteroids, and intralesional injection 
are suitable for mild disease (4). If there is sec-
ondary infection, the use of topical or oral antibi-
otics may be appropriate before applying topical 
steroids.
 Systemic corticosteroid therapy is usually 
needed for more severe disease. Prednisone is 
the most often used and fastest acting agent. Re-
currence is possible after steroid therapy is dis-
continued. More severe and recurrent disease is 
treated with immunosupressive medications, in-
cluding mycophenolate mofetil (9) and cyclospo-
rine A (10).
 Other treatments include recombinant human 
granulocyte-macrophage colony-stimulating fac-
tor (11), plasmapheresis with cyclophosphamide 
(12), and intravenous human imunoglobulin (13). 
A novel approach of topical treatment is the use 
of 0.1% tacrolimus cream twice daily, which is a 
macrolide antibiotic with a immunosuppressive ef-
fect (14,15). 
 In refractory cases, intravenous pulsed steroids 
(methylprednisone) or cyclosporine may be ben-
eficial (6). Diaminodiphenyl sulphone (Dapson) 
may also be an effective adjunct (6,16-17). Davis 
et al. published a case where hyperbaric oxygen 
was used to promote healing prior to the applica-
tion of a skin graft (18). One of the most intriguing 
new therapies for PG is infliximab. Infliximab is a 
monoclonal antibody with high affinity and speci-
ficity to TNF-alpha which neutralizes its biological 
activity (19). 
 Surgical therapy should be avoided because 
it may exacerbate the disease owing to pathergy 
(4,5,20). Aggressive debridement of PG wounds 
is usually contraindicated as well (20). Some pa-
tients with ulcerative colitis experience response 
to total colectomy (15).
 The prognosis of PG is generally good. Recur-
rences may occur, however, and residual scaring 
is common. Death from PG is rare, but it may oc-
cur due to an associated disease or as the result 
of therapy. 
CONCLUSION
 The management of PG continues to be a ther-
apeutic challenge. First line treatment is orally ad-
ministered corticosteroids, sometimes combined 
with a steroid sparing agent. Early treatment with 
immunosuppressive drugs is essential to control 
Figure 8. A few erosions and cicatrical tissue on 
the chest region
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the disease and prevent permanent scarring. Le-
sions may either pursue an acute progressive 
course or a chronic course with slow extension. 
It is often difficult to achieve control of aggressive 
cases of pyoderma gangrenosum. Furthermore, 
patients recalcitrant to one or many medications 
are frequently reported. Concomitant disease, in-
tolerance to a class of medications, and the pa-
tient’s response to prior therapies can help guide 
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